Related Experiment Videos
Inhibition of beta-adrenergic binding by fungal metabolites
1Department of Biology, University of Hartford, West Hartford, CT 06117.
Abstract:
Strains of Aspergillus flavus, Fusarium sp., Rhizopus sp. and Candida albicans all produced inhibitors of beta-adrenergic receptor binding; strains of Saccharomyces sp. and Schizosaccharomyces sp. did not. In tests with glutamic acid as the sole nutrient source, a Fusarium sp. produced four-fold larger amounts of inhibitor than the other fungi. The inhibitor from the Fusarium sp. was further purified by lyophilisation and sequential solvent extraction in chloroform, ethyl acetate and butanol; 60% of the original activity was recovered. The inhibitor had an estimated molecular size of 650 Da, and did not absorb light in the visible or ultraviolet range. When compared with a similar inhibitor from Escherichia coli, the Fusarium sp. inhibitor appeared to be a more potent inhibitor of beta-adrenergic and dopaminergic binding to mammalian cells.
Insights
Certain fungi, including Fusarium, produce compounds that inhibit beta-adrenergic receptor binding. This fungal inhibitor is more potent than a similar compound from E. coli, suggesting potential therapeutic applications.
Area of Science:
- Microbiology
- Pharmacology
- Biochemistry
Background:
- Fungal metabolites can possess biological activity.
- Beta-adrenergic receptors are crucial in physiological processes.
- Inhibitors of receptor binding have therapeutic potential.
Purpose of the Study:
- To investigate the production of beta-adrenergic receptor binding inhibitors by various fungal species.
- To characterize and compare a novel inhibitor from Fusarium sp. with known inhibitors.
Main Methods:
- Screening of fungal strains (Aspergillus flavus, Fusarium sp., Rhizopus sp., Candida albicans, Saccharomyces sp., Schizosaccharomyces sp.) for inhibitor production.
- Cultivation of Fusarium sp. using glutamic acid as a nutrient source.
- Purification of the inhibitor via lyophilization and sequential solvent extraction.
- Estimation of molecular size and UV-Vis spectrophotometry.
- Comparative analysis of inhibitory activity against mammalian cell receptors.
Main Results:
- Aspergillus flavus, Fusarium sp., Rhizopus sp., and Candida albicans produced beta-adrenergic receptor binding inhibitors, while Saccharomyces sp. and Schizosaccharomyces sp. did not.
- Fusarium sp. produced significantly higher amounts of inhibitor.
- Purification yielded 60% of the original activity, revealing an inhibitor with a molecular size of approximately 650 Da.
- The Fusarium sp. inhibitor demonstrated greater potency in inhibiting beta-adrenergic and dopaminergic binding compared to an Escherichia coli-derived inhibitor.
Conclusions:
- Specific fungal species, notably Fusarium, are sources of beta-adrenergic receptor binding inhibitors.
- The purified Fusarium inhibitor is a potent antagonist of beta-adrenergic and dopaminergic signaling.
- This fungal metabolite warrants further investigation for its pharmacological potential.